Nucleic acid aptamer treatment for X-linked hypophosphatemic rickets receives US FDA Orphan Drug Designation and Pediatric Rare Disease Designation
The long-acting sclerostin-loop3 nucleic acid aptamer Apc001OA for the treatment of XLH, developed by Prof. ZHANG Ge [Law Sau Fai Institute for Advancing Translational Medicine in Bone&Joint Diseases, Hong Kong Baptist University (HKBU)], Prof. ZHANG Zhenlin (Osteoporosis and Bone Diseases, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine) and Aptacure Therapeutics Ltd., was granted Orphan Drug Designation (DRU-2023-9894) and Pediatric Rare Disease
The Aptamer Long-lasting Modification Strategy project by TMBJ has won the second prize at the 9th Hong Kong University Student Innovation and Entrepreneurship Competition.
The Hong Kong New Generation Cultural Association held the 9th Hong Kong University Student Innovation and Entrepreneurship Competition on June 2, 2023. The competition covered various categories, including life science. A total of 385 projects from 21 tertiary institutions participated in this edition of the competition. The team from the Law Sau Fai Institute for Advancing Translational Medicine in Bone & Joint Diseases (TMBJ) Hong Kong Baptist University, won the second prize in the life scie
The project ‘Sclerostin Aptamer for treatment of osteogenesis imperfecta’ won the third prize at the 9th Hong Kong University Student Innovation and Entrepreneurship Competition
The project ‘Sclerostin Aptamer for treatment of osteogenesis imperfecta’ won the third prize at the 9th Hong Kong University Student Innovation and Entrepreneurship Competition
The Project of “Development Of Small-molecule Inhibitors Targeting Sclerostin Loop3 For Reversing Established Osteoporosis” Was Funded By Innovation And Technology Fund
Professor Zhang Ge, together with Professor Lei Jinping from Sun Yat-sen University, applied for the Guangdong-Hong Kong Technology Cooperation Funding Scheme (TCFS) titled "Development of Small-molecule Inhibitors Targeting Sclerostin Loop3 for Reversing Established Osteoporosis".
Apc001 [Jointly Developed by Law Sau Fai Institute for Advancing Translational Medicine in Bone&Joint Diseases (TMBJ), HKBU and Aptacure] was Exhibited at BIOHK 2022.
Apc001 [Jointly Developed by Law Sau Fai Institute for Advancing Translational Medicine in Bone&Joint Diseases (TMBJ), HKBU and Aptacure] was Exhibited at BIOHK 2022.
Apc001 from the Law Sau Fai Institute for Advancing Translational Medicine in Bone & Joint Disease has been recognized as representative achievement in the field of medical and health sciences for the
Apc001 from the Law Sau Fai Institute for Advancing Translational Medicine in Bone & Joint Disease has been recognized as representative achievement in the field of medical and health sciences for the 25th anniversary of Hong Kong’s return to the Motherland
Apc001OA from the Law Sau Fai Institute for Advancing Translational Medicine in Bone & Joint Disease was granted as Hong Kong First Rare Pediatric Designation for the Treatment of Osteogenesis Imperfe
Apc001OA from the Law Sau Fai Institute for Advancing Translational Medicine in Bone & Joint Disease was granted as Hong Kong First Rare Pediatric Designation for the Treatment of Osteogenesis Imperfecta
Scientist from the Institute of Bone and Joint Disease Translational Medicine at Hong Kong Baptist University received the Best Poster Award in the BlueSky project
Scientist from the Institute of Bone and Joint Disease Translational Medicine at Hong Kong Baptist University received the Best Poster Award in the BlueSky project
Institute for Advancing Translational Medicine in Bone & Joint Diseases (TMBJ), in collaboration with Aptacure, showcased Apc001 at the "Innovation and Technology Carnival 2022"
Institute for Advancing Translational Medicine in Bone & Joint Diseases (TMBJ), in collaboration with Aptacure, showcased Apc001 at the "Innovation and Technology Carnival 2022"
Joint Publication on Long-lasting Therapeutic Nucleic Acid Aptamer Targeting Strategies by Institute for Advancing Translational Medicine in Bone & Joint Diseases (TMBJ) and The Chinese University of
Joint Publication on Long-lasting Therapeutic Nucleic Acid Aptamer Targeting Strategies by Institute for Advancing Translational Medicine in Bone & Joint Diseases (TMBJ) and The Chinese University of Hong Kong
Imperial College London (School of Medicine) and Hong Kong Baptist University discovered a close association between mutations in specific regions of the sclerostin and cardiovascular abnormalities
Imperial College London (School of Medicine) and Hong Kong Baptist University discovered a close association between mutations in specific regions of the sclerostin and cardiovascular abnormalities
Hong Kong Baptist University Leads University-company Collaborative Innovation in the Field of New Strategies for Osteogenic Treatment: From Molecular Target to Aptamer Drug Discovery towards U.S. FDA
Hong Kong Baptist University Leads University-company Collaborative Innovation in the Field of New Strategies for Osteogenic Treatment: From Molecular Target to Aptamer Drug Discovery towards U.S. FDA Orphan Drug Designation
Professor Aiping Lyu from the Law Sau Fai Institute For Advancing Translational Medicine In Bone&Joint Diseases of Hong Kong Baptist University was elected as a member of The Academy of Europe
Professor Aiping Lyu from the Law Sau Fai Institute For Advancing Translational Medicine In Bone&Joint Diseases of Hong Kong Baptist University was elected as a member of The Academy of Europe
Professor Zhang Ge’s team from the Law Institute for Translational Medicine of Bone and Joint Diseases of Hong Kong Baptist University, research team from the Chinese University of Hong Kong and Shan
Professor Zhang Ge’s team from the Law Institute for Translational Medicine of Bone and Joint Diseases of Hong Kong Baptist University, research team from the Chinese University of Hong Kong and Shanghai Jiao Tong University jointly published a systematic review of sclerostin inhibitors drug discovery
The team led by Zhang Baoting and scientists from the Institute of Translational Medicine in Bone & Joint Diseases (TMBJ) at Hong Kong Baptist University, under Luo Shouhui, have proposed a new strate
The team led by Zhang Baoting and scientists from the Institute of Translational Medicine in Bone & Joint Diseases (TMBJ) at Hong Kong Baptist University, under Luo Shouhui, have proposed a new strategy for virtual screening of miRNA targets.
Prof. Zhang Ge, the Deputy Director of TMBJ was invited to attend the 10th national conference on osteoporosis and bone mineral salt diseases of Chinese medical association.
Prof. Zhang Ge, the Deputy Director of TMBJ was invited to attend the 10th national conference on osteoporosis and bone mineral salt diseases of Chinese medical association.
Chinese university of Hong Kong - Hong Kong Baptist university jointly trained doctoral students attended the 2018 Postgraduate Symposium on Chinese Medicinal Sciences
Chinese university of Hong Kong - Hong Kong Baptist university jointly trained doctoral students attended the 2018 Postgraduate Symposium on Chinese Medicinal Sciences
About Institute
‘Institute for Advancing Translational Medicine in Bone & Joint Diseases (TMBJ)' in Hong Kong Baptist University is initiated by Prof. Aiping Lu (M.D., Ph.D.), the Chair Professor of Integrated Traditional Chinese and Western Medicine from School of Chinese Medicine in Hong Kong Baptist University, and Prof. Ge Zhang (M.D.), the Associate Dean of School of Chinese Medicine in Hong Kong Baptist University . TMBJ was established on September 1st, 2012. Prof. Aiping Lu was the Director of TMBJ. Until 2019. Prof Ge Zhang is the Director of TMBJ.......more
Message from Director
Welcome to visit homepage of Institute for 'Advancing Translational Medicine in Bone & Joint Diseases (TMBJ)'. Through this website, we hope to provide you with more information and resource that will assist you in acquiring knowledge about translational medicine in bone & joint diseases as well as getting to know our institute and also share some data service in the meanwhile.......more
